Now Reading: Shilpa Medicare’s Jadcherla unit gets GMP certification from AGES Austria
-
01
Shilpa Medicare’s Jadcherla unit gets GMP certification from AGES Austria
Shilpa Medicare’s Jadcherla unit gets GMP certification from AGES Austria
Shilpa Medicare’s Unit 4 in Jadcherla, Telangana, has received Good Manufacturing Practice (GMP) certification from AGES, Austria, following an inspection from July 27 to July 30, 2026. The company announced the certification in a regulatory filing on October 10. Unit 4 manufactures, tests, and distributes sterile injections and non-sterile tablets and capsules for markets in Europe and other global markets. Shilpa Medicare is headquartered in Raichur, Karnataka.
In a separate development, Shilpa Medicare received final approval from the Subject Expert Committee (SEC) under CDSCO to market OERIS, an extended-release ondansetron injection for chemotherapy-induced nausea and vomiting. The product provides protection for up to five days after a single dose and is patent-protected in India until 2039. The company plans to launch OERIS commercially in India after receiving final marketing authorisation.
Indian Opinion Analysis
Both outlets report the GMP certification identically, leading with the regulatory filing and the July inspection dates. cnbctv18 adds the OERIS approval as a separate development, while medicaldialogues sticks solely to the certification news. The coverage is uniform straight reporting with no discernible slant from either source. Neither outlet offers commentary on the commercial significance or regulatory hurdles. The next concrete step is Shilpa Medicare’s planned commercial launch of OERIS after receiving final marketing authorisation.
Coverage: 2 sources, 2 neutral
Sources (2): cnbctv18.com (neutral report), medicaldialogues.in (neutral report)
This brief was synthesised by AI from the 2 sources linked above, so one read covers every framing they carry. Methodology and corrections.
